← Back to Home

Finding Anti-Aging Targets Through Gene Expression: SRSF1 Extends Median Lifespan in Aged Mice by 14%

Researchers used machine learning to screen for genes that could alter the state of aging cells, then tracked cellular function and mouse survival. SRSF1 provided preliminary evidence of slowing frailty, but delivery, dosing, and safety remain hurdles between a small animal study and a human therapy.

By SURL BioNews

Can reducing cellular markers of aging improve physical function, or even extend life? A study published in Nature Aging took this question from human skin cells to aged mice: increasing expression of the RNA-processing factor SRSF1 reduced several cellular hallmarks of aging, slowed the progression of frailty in mice, and extended median lifespan by 14% compared with controls. These are preclinical findings that support further research; they do not yet establish that humans could experience the same effects.

The Wyss Institute at Harvard University and collaborating teams first trained a machine learning model on gene expression data from 464 fibroblast samples to estimate the cells’ “transcriptomic age.” The researchers then increased the expression of candidate genes one at a time, using model scores to screen for factors that could shift aged cells toward a younger gene expression pattern. The tool is intended to help select experimental targets; a younger score alone still requires validation through functional experiments.

SRSF1 stood out in the screening. It participates in RNA splicing, influencing how RNA is assembled into messages for protein production. According to the research data summary, increasing SRSF1 expression reduced cellular senescence, proteostasis stress, and inflammatory signaling, while the fibroblasts retained their original identity. This addresses a challenge in cellular reprogramming: how to improve the aging state while preserving mature cells’ original functions.

The team then delivered the SRSF1 gene using an adeno-associated virus (AAV) vector with a preference for the liver. A Wyss press release and the same release published on Brightsurf reported that treated mice accumulated frailty more slowly and showed an increase in median lifespan. The summary of GEO dataset GSE325735, indexed by OmicsDI, further specified a 44% reduction in frailty progression, but each group contained only 9 to 10 animals; larger studies are needed to confirm the consistency of these results.

Why an intervention in the liver was accompanied by benefits throughout the body remains unanswered. The researchers proposed that changes in the liver might influence other tissues through signals within the body, but how changes in RNA splicing connect to improved function and differences in survival remains unclear. The current findings are also insufficient to demonstrate that all organs returned to a younger state simultaneously.

Before moving toward a therapy, the team still needs to address delivery methods and dose control, and clarify systemic effects and long-term safety. The advance in this study lies in connecting screening results from a gene expression model with evidence from cellular function and animal survival. Whether the benefits can be replicated, how long they last, and whether the approach can be used safely in humans remain questions for the next stage of research.

References

  1. Wyss Institute at Harvard University
  2. OmicsDI
  3. Brightsurf — Wyss Institute news release